Cargando…
Hydroxychloroquine in IgA nephropathy: a systematic review
BACKGROUND: Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. METHODS: Electronic da...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604447/ https://www.ncbi.nlm.nih.gov/pubmed/34779707 http://dx.doi.org/10.1080/0886022X.2021.2000875 |
_version_ | 1784601963073110016 |
---|---|
author | Stefan, Gabriel Mircescu, Gabriel |
author_facet | Stefan, Gabriel Mircescu, Gabriel |
author_sort | Stefan, Gabriel |
collection | PubMed |
description | BACKGROUND: Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. METHODS: Electronic databases were searched for randomized, cohort, or case-control studies with IgAN biopsy-proven patients comparing the effects of HCQ with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or immunosuppression on proteinuria reduction. RESULTS: Five studies, one randomized and three observational, involving a total of 504 patients, were eligible for inclusion. Overall, there was a tendency of HCQ treatment to reduce proteinuria. In the studies where the control arm was supportive therapy, HCQ significantly reduced proteinuria at 6 months. However, in the studies that compared HCQ to immunosuppressive therapy, we found no difference in proteinuria reduction. HCQ had no impact on eGFR. CONCLUSION: HCQ seems to be an efficient alternative therapy for patients with IgAN who insufficiently respond to conventional therapy. However, ethnically diverse randomized controlled studies with long-term follow-up are needed. |
format | Online Article Text |
id | pubmed-8604447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-86044472021-11-20 Hydroxychloroquine in IgA nephropathy: a systematic review Stefan, Gabriel Mircescu, Gabriel Ren Fail Clinical Study BACKGROUND: Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. METHODS: Electronic databases were searched for randomized, cohort, or case-control studies with IgAN biopsy-proven patients comparing the effects of HCQ with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or immunosuppression on proteinuria reduction. RESULTS: Five studies, one randomized and three observational, involving a total of 504 patients, were eligible for inclusion. Overall, there was a tendency of HCQ treatment to reduce proteinuria. In the studies where the control arm was supportive therapy, HCQ significantly reduced proteinuria at 6 months. However, in the studies that compared HCQ to immunosuppressive therapy, we found no difference in proteinuria reduction. HCQ had no impact on eGFR. CONCLUSION: HCQ seems to be an efficient alternative therapy for patients with IgAN who insufficiently respond to conventional therapy. However, ethnically diverse randomized controlled studies with long-term follow-up are needed. Taylor & Francis 2021-11-15 /pmc/articles/PMC8604447/ /pubmed/34779707 http://dx.doi.org/10.1080/0886022X.2021.2000875 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Stefan, Gabriel Mircescu, Gabriel Hydroxychloroquine in IgA nephropathy: a systematic review |
title | Hydroxychloroquine in IgA nephropathy: a systematic review |
title_full | Hydroxychloroquine in IgA nephropathy: a systematic review |
title_fullStr | Hydroxychloroquine in IgA nephropathy: a systematic review |
title_full_unstemmed | Hydroxychloroquine in IgA nephropathy: a systematic review |
title_short | Hydroxychloroquine in IgA nephropathy: a systematic review |
title_sort | hydroxychloroquine in iga nephropathy: a systematic review |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604447/ https://www.ncbi.nlm.nih.gov/pubmed/34779707 http://dx.doi.org/10.1080/0886022X.2021.2000875 |
work_keys_str_mv | AT stefangabriel hydroxychloroquineiniganephropathyasystematicreview AT mircescugabriel hydroxychloroquineiniganephropathyasystematicreview |